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rs3751143
rs208294Inﬂammation is a key factor in the onset andprogression of Alzheimer's disease (AD). The P2X7 receptor (P2X7R)
is increasingly recognized as key pro-inﬂammatory receptor. A recent study has shown that activation ofmicrog-
lia by amyloidβ (Aβ) and associated release of IL-1β, requires P2X7R expression. In this studywe assessed by RT-
PCR in genomic DNA samples, the frequency of two single-nucleotide polymorphisms (SNP) of P2X7R in AD
patients compared to age-matched non demented elderly. Our data show that the 489CNT SNP was signiﬁcantly
less frequent in AD patients than in controls (p = 0.01), whereas there was no statistical difference in 1513ANC
frequency in either groups. In addition, presence of the 1513C allele and absence of the 489C allele decreased the
probability of having AD by about four fold. In conclusion, our data show a strong negative association between
the P2X7R 489CNT polymorphism and AD, especially in the presence of the 1513C allele.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Alzheimer's disease (AD) is the leading cause of dementia in the
elderly and the number of patients is increasing due to the increment
of the average lifespan. There is little doubt that inﬂammation is a key
factor in the initiation and progression of AD (Niranjan, 2013; Zhang
et al., 2013). It has in fact been shown that overt neuroinﬂammation
and increased central nervous system IL-1β levels are present only in
AD patients and not in healthy elderly subjects, even in the presence
of the typical AD plaques (Rao et al., 2011). The P2X7R is a potent acti-
vator of the NLRP3 (NOD-like receptor family, pyrin domain containing
3) inﬂammasome and a strong stimulant of IL-1β release, besides being
also involved in antigen presentation, endosome–lysosome fusion and
phagocytosis (Di Virgilio, 2013; Rayah et al., 2012). In a transgenic
murine model of AD P2X7R is overexpressed by glial cells surroundingCHD, coronaryheart disease;CI,
OR, odds ratio; P2X7R, P2X7 re-
ine, Gerontology, and Clinical
”, Corso Gioveca 203, 44100
lzoni@unife.it (S. Falzoni),
pollone),
irgilio).
. This is an open access article underAβ plaques, and is a necessary requirement for Aβ-stimulated IL-1β
release in vivo (Parvathenani et al., 2003; Sanz et al., 2009). In addition,
P2X7 is up-modulated bymicroglia isolated frombrains fromAD patients
(Parvathenani et al., 2003; McLarnon et al., 2006).
The P2X7R, a member of the P2X subfamily of purinergic receptors, is
a cation-selective ion channel activated by extracellular ATP. When over-
activated, P2XR undergoes a channel-to-pore transition that causes the
opening of a non-selective plasmamembrane pore permeable to aqueous
solutes up to aMWof 900 D. The precise physiological function of P2X7R
is as yet unknown, but rather intriguingly this gene is highly polymorphic,
with over thirty single-nucleotide polymorphisms (SNPs) described
(Backlund et al., 2012; http://www.genecards.org/cgi-bin/carddisp.pl?
gene=P2RX7&search=97e20c4c94f763ef865b40c278da3b2d).
Recently, attention has been focused on two SNPs, 1513ANC
(rs3751143) and 489CNT (rs208294), leading the substitution of gluta-
mate for alanine at position 496 (E496A) and histidine for tyrosine at
position 155 (H155Y), respectively. The 1513ANC substitution, localized
in the carboxyl-terminal cytoplasmic tail of the receptor, is associated
in heterozygosis (AC) with a 50% decrease in P2X7R responses, and in
homozygosis (CC) to a near complete loss of P2X7R function (Gu et al.,
2001). This SNP has been linked with different diseases such as a famil-
ial form of chronic lymphocytic leukemia, the follicular variant of
papillary thyroid cancer, and increased susceptibility to tuberculosis in-
fections (Sluyter and Stokes, 2011). The 489CNT SNP, localized in P2X7Rthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 2
Allelic, genotypic and haplotypic frequencies of 1513ANC and 489CNT polymorphisms in
the control and AD groups.
Control AD p
Alleles n (%)
1513ANC
A 220 (74) 128 (76) 0.74a
C 76 (26) 40 (24)
Total 296 168
489CNT
C 130 (44) 98 (58) 0.0037a
T 166 (56) 70 (42)
Total 296 168
Genotypes n (%)
1513ANC
AA 83 (55) 52 (62) 0.45b
AC 54 (36) 24 (29)
CC 11 (7) 8 (9)
Total 148 84
489CNT
CC 30 (20) 27 (32) 0.01b
CT 70 (47) 44 (52)
TT 48 (33) 13 (16)
Total 148 84
Haplotypes n (%)
A/C 113 (38) 76 (45) 0.0022b
A/T 107 (36) 52 (31)
C/T 59 (20) 18 (11)
C/C 17 (6) 22 (13)
Total 296 168
Bold entries indicate a signiﬁcant p value.
a Fisher exact test.
b Chi-square test.
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to any disease (Cabrini et al., 2005; Sluyter and Stokes, 2011).
The purpose of this study was to assess the frequency of 1513ANC
and 489CNT in AD patients versus age-matched subjects.
2. Methods
2.1. Study participants
The study population comprised 84 Caucasian Late Onset Alzheimer's
disease subjects (age range 65 to 88 years, average age 78 ± 6) diag-
nosed according to theNational Institute of Neurological and Communi-
cative Disorders and Stroke/Alzheimer's Disease and Related Disorders
Association (NINCDS-ADRDA) criteria. Consecutive patients referring
to the Day Hospital Services (Ferrara, Italy) were enrolled during a
four-year period. Subjects affected by severe congestive heart failure
(New York Heart Association classes III–IV), severe liver or kidney
disease, severe chronic obstructive pulmonary disease, or cancer were
excluded. For neuropsychological assessment, all patients were given
a battery of tests as previously described (Zuliani et al., 2007). 148
free-living elderly subjects (control group) (age range 65 to 93 years,
average age 73 ± 5.6) were recruited among those referring to the
“Ageing Center” of University of Chieti (Italy). Patientswith cerebrovas-
cular lesions, mixed or vascular dementia or clinically signiﬁcant neuro-
logic disease due to conditions other than AD, or major depressive
disorder were excluded. All control patients enrolled in the control
group were requested to have a Mini Mental State Examination
(MMSE) score of 28 or higher. Written informed consent was obtained
from participants and/or legally authorized representatives. The study
was approved by the local ethics review committee.
2.2. P2X7R polymorphism analysis
Genomic DNA was extracted from blood leukocytes with the salting
outmethod. 1513ANC and 489CNT SNPswere analyzed in genomic DNA
sampleswith the TaqManMGBprobe technique as previously described
(Cabrini et al., 2005).
2.3. Statistical analysis
We analyzed P2X7R polymorphisms, alleles, genotypes and haplo-
types by Arlequin 3.5.1.2 software (Excofﬁer et al., 2007). Statistical
analysis was performed using StatView software package (SAS Institute
Inc., Cary, NC) and GraphPad Prism 6.0 software (Graphpad Software,
San Diego, CA, USA). Signiﬁcance was assumed for p b 0.05.
3. Results and discussion
Baseline characteristics of subjects of both groups are shown in
Table 1. The frequency of patients with hypertension, coronary heart dis-
ease (CHD) and diabetes is signiﬁcantly higher in the AD group compared
to the control group.
Table 2 shows frequencies of 1513ANC and 489CNT SNPs from non-
demented control subjects and AD patients. Both P2X7R polymorphismsTable 1
Baseline characteristics of subjects of control and AD groups.
Control AD pa
Females 118 (80) 63 (75) 0.84
Hypertension 52 (35) 53 (63) 0.02
CHD 6 (4) 14 (17) 0.004
Diabetes 7 (5) 14 (17) 0.009
Smoke 14 (10) 8 (9) 1
Exposed individuals classiﬁed for sex, hypertension, CHD (coronary heart disease), diabetes,
and current smoking habits are indicated as number of subjects (%).
a Fisher exact test.were inHardy–Weinberg equilibrium in both control andADpopulations
(1513ANC: controls χ2: 0.29, p = 0.59; AD patients χ2: 3.7, p = 0.054;
489CNT controls χ2: 0.24, p = 0.62; AD patients χ2: 0.08, p = 0.78).
The minor allele frequency of 1513ANC and 489CNT polymorphisms
was comparable with frequencies found in other published European
reports (Cabrini et al., 2005; Sluyter and Stokes, 2011). Curiously, we
have observed an increase, although not signiﬁcant, of the frequency
of the 1513ANC and 489CNT polymorphisms and 1513CC and 489TT ho-
mozygotes in control subjects compared to values obtained previously
in our laboratory by analyzing these polymorphisms and genotypes in
young volunteers (Cabrini et al., 2005). This increase could be due to
the difference in age between the two groups, similar to results obtain-
ed by Zhang et al. (2003).
When the possible relationship between the 1513ANC polymor-
phism with AD was analyzed, no signiﬁcant association was detected.
Instead, analysis of the 489CNT polymorphism frequency showed an
increase in the 489C allele and the 489CC genotype in AD patients com-
pared to controls. Thus, the 489CC genotype was more frequent than
489TT in AD, whereas in elderly non-demented 489TT was more fre-
quent than 489CC.
Analysis of haplotypes revealed a different distribution between
controls and AD population. To examine these differences, subjects
were subdivided on the basis of the presence/absence of both alleles
in combination; because the most common genotype for 1513ANC and
489CNT P2X7R polymorphisms was AA and CT, respectively, the most
frequent subgroup, was formed by the absence of the 1513C allele and
the presence of the 489C allele; thus, this subgroup was taken as refer-
ence for analysis. Odd's ratio (OR) and 95% conﬁdence interval (CI)
were computed to assess the possible association between alleles–geno-
types of 1513ANC and 489CNT P2X7R polymorphisms and the risk of hav-
ing a diagnosis of AD (Table 3). The presence of the 1513C allele and the
absence of the 489C allele decreased the probability of having AD by
about four fold versus the reference subgroup.
The presence of the 1513C allele causes a severe decrease in
P2X7R-associated responses. This receptor is well known for its
pro-inﬂammatory activity (Bours et al., 2011), thus a reduced function
Table 3
Relationship between combination of 1513ANC and 489CNT genotypes and risk of receiving
the diagnosis of Late Onset Alzheimer's disease.
1513A N C 489C N T Control n (%) AD
n (%)
OR
(95% C.I.)
pa
Absent C Absent C 19 (12.8) 8 (9.5) 0.62 (0.25–1.66) 0.38
Absent C Present C 64 (43.2) 44 (52.4) Reference
Present C Absent C 29 (19.6) 5 (6.0) 0.25 (0.09–0.71) 0.007
Present C Present C 36 (24.3) 27 (32.1) 1.08 (0.58–2.0) 0.87
Total 148 84
Bold entries indicate a signiﬁcant p value.
a Fisher exact test.
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associated to an increase in Aβ phagocytosis in microglia (Ni et al.,
2013). On the other hand, the P2X7R ectodomain, in particular the
“dolphin nose” region (residues 115–168) appears to be associated
with phagocytosis (Wiley and Gu, 2012); the presence at residue 155
of the 489TT genotype inside this region may potentiate phagocytosis
activity of P2X7R, and subsequent Aβ elimination. Fiala et al. have
shown that monocyte and macrophages from AD patients are inefﬁ-
cient in Aβ phagocytosis and clearance, it is not clear if it was the
cause and/or a consequence of the disease (Fiala et al., 2005). However,
control of Aβ deposition is certainly an important step in the onset and
development of the disease and P2X7 could play an important role in
this process and may be useful as target for prevention or treatment
therapies; actually there are only palliative therapies for symptoms.
Further studies will certainly help to solve this issue.
4. Conclusions
In conclusion, this manuscript shows that the 489CNT P2X7 poly-
morphism alone or in concomitance with 1513C allele of 1513ANC
P2X7R polymorphism are less frequent in Alzheimer's disease (AD)
patients than in age-matched non-demented elderly. This is the ﬁrst
study that associates the 489CNT P2X7R polymorphism with a disease.
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